Type 1 ribosome-inactivating proteins are the most abundant proteins in iris (Iris hollandica var. Professor Blaauw) bulbs: characterization and molecular cloning

The most abundant protein of Iris bulbs has been identified as a type 1 ribosome-inactivating protein (RIP). Analysis of the purified proteins and molecular cloning of the corresponding cDNAs demonstrated that this type 1 RIP is a mixture of three isoforms that exhibit a high degree of sequence identity and have similar, though not identical, ribosome-inactivating and polynucleotide:adenosine glycosidase activities. The accumulation of large quantities of type 1 RIP in a vegetative storage organ suggests that this presumed defence-related protein also plays a role in the nitrogen-storage metabolism of the bulb.

Download Full-text

Comparison of the Embryotoxic Effects of Saporin, Agrostin (Type 1 Ribosome-Inactivating Proteins) and Ricin (a Type 2 Ribosome-Inactivating Protein

Pharmacology & Toxicology ◽

10.1034/j.1600-0773.2001.d01-121.x ◽

2001 ◽

Vol 88 (6) ◽

pp. 300-303 ◽

Cited By ~ 3

Author(s):

Wood-Yee Chan ◽

Tzi-Bun Ng

Keyword(s):

Ribosome Inactivating Protein ◽

Ribosome Inactivating Proteins ◽

Embryotoxic Effects ◽

Ricin A

Download Full-text

Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells

Toxins ◽

10.3390/toxins13100684 ◽

2021 ◽

Vol 13 (10) ◽

pp. 684

Author(s):

Rossella Rotondo ◽

Sara Ragucci ◽

Salvatore Castaldo ◽

Maria Antonietta Oliva ◽

Nicola Landi ◽

...

Keyword(s):

Cell Lines ◽

Chemotherapeutic Agent ◽

Primary Cells ◽

Glioblastoma Cells ◽

Ribosome Inactivating Protein ◽

Primary Glioblastoma ◽

Ribosome Inactivating Proteins ◽

Primary Cell Lines ◽

Target Cancer

Ribosome-inactivating proteins (RIPs) are found in several edible plants and are well characterized. Many studies highlight their use in cancer therapy, alone or as immunoconjugates, linked to monoclonal antibodies directed against target cancer cells. In this context, we investigate the cytotoxicity of quinoin, a novel type 1 RIP from quinoa seeds, on human continuous and primary glioblastoma cell lines. The cytotoxic effect of quinoin was assayed on human continuous glioblastoma U87Mg cells. Moreover, considering that common conventional glioblastoma multiforme (GBM) cell lines are genetically different from the tumors from which they derive, the cytotoxicity of quinoin was subsequently tested towards primary cells NULU and ZAR (two cell lines established from patients’ gliomas), also in combination with the chemotherapeutic agent temozolomide (TMZ), currently used in glioblastoma treatment. The present study demonstrated that quinoin (2.5 and 5.0 nM) strongly reduced glioblastoma cells’ growth. The mechanisms responsible for the inhibitory action of quinoin are different in the tested primary cell lines, reproducing the heterogeneous response of glioblastoma cells. Interestingly, primary cells treated with quinoin in combination with TMZ were more sensitive to the treatment. Overall, our data highlight that quinoin could represent a novel tool for glioblastoma therapy and a possible adjuvant for the treatment of the disease in combination with TMZ, alone or as possible immunoconjugates/nanoconstructs.

Download Full-text